Sign In
Buy EYPT
$12.25
-0.610 (-4.74%)
At Close: Jul 31, 2026
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments
07:00am, Wednesday, 07'th May 2025
– Enrollment continues to exceed expectations in DURAVYU ™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025
07:00am, Wednesday, 30'th Apr 2025
WATERTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives o
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Wednesday, 16'th Apr 2025
WATERTOWN, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of pati
EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
07:00am, Thursday, 27'th Mar 2025
WATERTOWN, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives o
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Monday, 17'th Mar 2025
WATERTOWN, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of pati
EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript
02:51pm, Wednesday, 05'th Mar 2025
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Ramiro Ribeiro -
EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say
10:30am, Wednesday, 05'th Mar 2025
Although the revenue and EPS for EyePoint Pharmaceuticals (EYPT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compa
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates
09:25am, Wednesday, 05'th Mar 2025
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.33 per share a year ago.
EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments
07:00am, Wednesday, 05'th Mar 2025
– Enrollment exceeding expectations in DURAVYU ™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule – – Positive Phase 2 VERONA clinical trial
EyePoint Announces Participation at Upcoming Investor Conferences
07:00am, Tuesday, 04'th Mar 2025
WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives o
EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025
07:00am, Wednesday, 26'th Feb 2025
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of
EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference
07:00am, Tuesday, 25'th Feb 2025
– Company presentation scheduled on Tuesday, March 4 th at 9:10am ET – – EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal program in wet AMD and additional subgroup a
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Monday, 17'th Feb 2025
WATERTOWN, Mass., Feb. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie
EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival
12:39pm, Thursday, 30'th Jan 2025
EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections required compared to Eylea and Vabysmo. Positive Phase 2 DME data and ongoin
EyePoint to Present at Guggenheim SMID Cap Biotech Conference
07:00am, Thursday, 30'th Jan 2025
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of
